Benchmark analyst Robert Wasserman reiterates Emergent BioSolutions (NYSE:EBS) with a Buy and maintains $22 price target.
Benchmark Reiterates Buy on Emergent BioSolutions, Maintains $22 Price Target
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.